Bently P Doonan, MD - Research

Research at a glance

Top areas of exploration

Antigen Presentation , 4 publications
Melanoma , 3 publications
CD4-Positive T-Lymphocytes , 3 publications
Autophagy , 3 publications

Research activity

18 publications

326 citations

Why is this important?

Active clinical trials

Oral IRAK-4 inhibitor CA-4948 in combination with Pembrolizumab following stereotactic radiosurgery

This phase I/II trial will investigate the use of the novel oral IRAK-4 inhibitor CA-4948 in combination with pembrolizumab therapy following stereotactic radiosurgery in patients with melanoma brain metastases (MBM). The investigators hypothesize鈥�

Investigator: Bently P Doonan
Status: Accepting Candidates
Ages: 18 Years - 99 Years
Sexes: All

My publications

18 publications

2023

Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK Inhibitors.

Oncology (Williston Park, N.Y.)

鈥�

2023

Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases

Clinical Cancer Research

2022

GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.

International journal of molecular sciences

鈥�

2022

Peptide Modification Diminishes HLA Class II-restricted CD4+ T Cell Recognition of Prostate Cancer Cells.

International journal of molecular sciences

鈥�

2019

Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.

Journal of cellular biochemistry

鈥�

BOB体育

Bently P Doonan, MD : Research

Research at a glance

Top areas of exploration

Research activity

Active clinical trials

My publications

Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK Inhibitors.

Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases

GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.

Peptide Modification Diminishes HLA Class II-restricted CD4+ T Cell Recognition of Prostate Cancer Cells.

Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.

BOB体育

Research at a glance

Top areas of exploration

Research activity

Active clinical trials

My publications

Filter publications

Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK Inhibitors.

Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases

GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.

Peptide Modification Diminishes HLA Class II-restricted CD4+ T Cell Recognition of Prostate Cancer Cells.

Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.